Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients

[1]  K. Matsuoka.  Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives , 2018, International Journal of Hematology.

[2]  R. Ionescu,et al.  Dysregulation of anergy‐related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells , 2016, International journal of rheumatic diseases.

[3]  E. Morand,et al.  Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus , 2016, Nature Medicine.

[4]  Hong Zhou,et al.  Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance , 2016, Molecular medicine reports.

[5]  L. Hennighausen,et al.  Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions , 2016, eLife.

[6]  Andreas Radbruch,et al.  Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus , 2015, Annals of the rheumatic diseases.

[7]  D. Klatzmann,et al.  Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. , 2015, Journal of autoimmunity.

[8]  R. Talaat,et al.  Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. , 2015, Cytokine.

[9]  I. Gunnarsson,et al.  IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment , 2015, BMC Immunology.

[10]  G. Burmester,et al.  Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE , 2015, Annals of the rheumatic diseases.

[11]  D. Klatzmann,et al.  Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes , 2015, Diabetes.

[12]  B. Blagoev,et al.  Simultaneous dissection and comparison of IL‐2 and IL‐15 signaling pathways by global quantitative phosphoproteomics , 2015, Proteomics.

[13]  B. Chung,et al.  The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients , 2015, Immunology.

[14]  B. Tönshoff,et al.  Akt-Dependent Enhanced Migratory Capacity of Th17 Cells from Children with Lupus Nephritis , 2014, The Journal of Immunology.

[15]  S. Berrih-Aknin,et al.  Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand , 2014, Cell Death and Disease.

[16]  J. Rathmell,et al.  The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. , 2014, Cell metabolism.

[17]  P. Bahadoran,et al.  Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. , 2014, JAMA dermatology.

[18]  P. Miossec,et al.  Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. , 2014, Autoimmunity reviews.

[19]  A. Mak,et al.  The Pathology of T Cells in Systemic Lupus Erythematosus , 2014, Journal of immunology research.

[20]  P. Wiland,et al.  Peripheral blood Th17/Treg imbalance in patients with low-active systemic lupus erythematosus. , 2014, Postepy higieny i medycyny doswiadczalnej.

[21]  D. Klatzmann,et al.  Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. , 2013, The lancet. Diabetes & endocrinology.

[22]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[23]  C. Doglioni,et al.  Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity , 2013, Clinical immunology.

[24]  T. Malek,et al.  IL-2R Signaling Is Essential for Functional Maturation of Regulatory T Cells during Thymic Development , 2013, The Journal of Immunology.

[25]  A. Hirao,et al.  PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. , 2021, Cell reports.

[26]  F. Carrat,et al.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.

[27]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[28]  C. Kallenberg,et al.  Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. , 2011, Clinical immunology.

[29]  Jiajia Cui,et al.  Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis , 2012, Rheumatology International.

[30]  Ming Li,et al.  Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[31]  C. Gordon,et al.  Effects of rituximab on resistant SLE disease including lung involvement , 2009, Lupus.

[32]  C. June,et al.  Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin1 , 2008, The Journal of Immunology.

[33]  S. Marks,et al.  B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus , 2007, Archives of Disease in Childhood.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[35]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[36]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[37]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.